GANX
Gain Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.11
−3.48%Oct 28, 2026, 23:35 UTC
Gain Therapeutics appointed Jeanette Weidner as Vice President, Finance, effective October 28, 2026, with an annual base salary of $275,000 and a target bonus of 35% of base salary.
Oct 1, 2026, 13:28 UTC
Gain Therapeutics presented positive Phase 1b open-label extension data for rexaceract, showing stable MDS-UPDRS motor scores and no disease progression in 12 evaluable participants who completed 12 months of daily oral administration by August 31, 2026.
Source:Sep 28, 2026, 20:38 UTC
Gain Therapeutics, Inc. Senior Vice President of Finance and principal financial and accounting officer Gianluca Fuggetta resigned effective September 30, 2026.
Sep 28, 2026, 20:38 UTC
Gain Therapeutics, Inc. appointed Gene Mack as interim Chief Financial Officer effective October 1, 2026.